Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURIPANC
NL-OMON60426Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and rintatolimod in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC) (2 arms), sponsored by Erasmus MC. Primary endpoints: Recommended phase II dose and Clinical benefit rate. Started Jan 2024; status: active, not recruiting.
02
Drugs
durvalumabrintatolimod
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on NL-OMON60426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60426.